Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; January 29, 2026 – (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 32,806 restricted stock units and 34,307 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, ...
Year-end report 2025, January – December Fourth quarter Order intake decreased by 4% to SEK 854 m (893). Organically, order intake increased by 3%Net sales increased by 18% to SEK 951 m (807). Organically, net sales increased by 23%Adjusted EBIT reached SEK 268 m (163), equal to a 28.2% (20.2) adjusted operating marginEBIT reached SEK 236 m (106), equal to a 24.8% (13.2) operating marginAdjusted profit after tax totaled SEK 209 m (131). Adjustments include a non-recurring tax effect of SEK 104 m, increasing the tax expense for the period. Adjusted basic earnings per share were SEK 4.17 (2....
Bokslutskommuniké 2025, januari – december Kvartalet Orderingången minskade med 4 % till 854 MSEK (893). Organiskt ökade orderingången med 3 %Nettoomsättningen ökade med 18 % till 951 MSEK (807). Organiskt ökade nettoomsättningen med 23 %Justerad EBIT uppgick till 268 MSEK (163), motsvarande en justerad rörelsemarginal på 28,2 % (20,2)EBIT uppgick till 236 MSEK (106), motsvarande en rörelsemarginal på 24,8 % (13,2)Justerat resultat efter skatt uppgick till 209 MSEK (131). Justeringar inkluderar en skatteeffekt av engångskaraktär om 104 MSEK som ökar periodens skattekostnad. Justerad vinst ...
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025 Company Announcement Net sales of DARZALEX® in 2025 totaled USD 14,351 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 21, 2026 – (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 14,351 million in 2025. Net trade sale...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.